Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death

Dasatinib and radotinib are oral BCR-ABL tyrosine kinase inhibitors that were developed as drugs for the treatment of chronic myeloid leukemia. We report here that the c-KIT (CD117) targeting with dasatinib and radotinib promotes acute myeloid leukemia (AML) cell death, and c-KIT endocytosis is esse...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Sook-Kyoung, Noh, Eui-Kyu, Kim, Jeong Yi, Jeong, Yoo Kyung, Jo, Jae-Cheol, Choi, Yunsuk, Koh, SuJin, Baek, Jin Ho, Min, Young Joo, Kim, Hawk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681687/
https://www.ncbi.nlm.nih.gov/pubmed/29127384
http://dx.doi.org/10.1038/s41598-017-15492-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681687/
https://www.ncbi.nlm.nih.gov/pubmed/29127384
http://dx.doi.org/10.1038/s41598-017-15492-5

Ejemplares similares